Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

702 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Vogel CL, et al. Among authors: tripathy d. J Clin Oncol. 2002 Feb 1;20(3):719-26. doi: 10.1200/JCO.2002.20.3.719. J Clin Oncol. 2002. PMID: 11821453 Corrected and republished. Clinical Trial.
RNA-Seq of Circulating Tumor Cells in Stage II-III Breast Cancer.
Lang JE, Ring A, Porras T, Kaur P, Forte VA, Mineyev N, Tripathy D, Press MF, Campo D. Lang JE, et al. Among authors: tripathy d. Ann Surg Oncol. 2018 Aug;25(8):2261-2270. doi: 10.1245/s10434-018-6540-4. Epub 2018 Jun 4. Ann Surg Oncol. 2018. PMID: 29868978 Free PMC article.
Clinical findings and outcomes of MRI staging of breast cancer in a diverse population.
Raghavendra A, Wecsler J, Ji L, Sheth P, Ricker C, Church T, Sposto R, Lang J, Sener S, Larsen L, Tripathy D. Raghavendra A, et al. Among authors: tripathy d. Breast Cancer Res Treat. 2019 Apr;174(2):315-324. doi: 10.1007/s10549-018-05084-w. Epub 2018 Dec 12. Breast Cancer Res Treat. 2019. PMID: 30542816 Free PMC article.
Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.
Caswell-Jin JL, McNamara K, Reiter JG, Sun R, Hu Z, Ma Z, Ding J, Suarez CJ, Tilk S, Raghavendra A, Forte V, Chin SF, Bardwell H, Provenzano E, Caldas C, Lang J, West R, Tripathy D, Press MF, Curtis C. Caswell-Jin JL, et al. Among authors: tripathy d. Nat Commun. 2019 Feb 8;10(1):657. doi: 10.1038/s41467-019-08593-4. Nat Commun. 2019. PMID: 30737380 Free PMC article.
Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.
Caswell-Jin JL, McNamara K, Reiter JG, Sun R, Hu Z, Ma Z, Ding J, Suarez CJ, Tilk S, Raghavendra A, Forte V, Chin SF, Bardwell H, Provenzano E, Caldas C, Lang J, West R, Tripathy D, Press MF, Curtis C. Caswell-Jin JL, et al. Among authors: tripathy d. Nat Commun. 2019 May 30;10(1):2433. doi: 10.1038/s41467-019-10456-x. Nat Commun. 2019. PMID: 31147552 Free PMC article.
702 results